Cargando…
Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2...
Autores principales: | Koleini, Navid, Nickel, Barbara E., Wang, Jie, Roveimiab, Zeinab, Fandrich, Robert R., Kirshenbaum, Lorrie A., Cattini, Peter A., Kardami, Elissavet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675643/ https://www.ncbi.nlm.nih.gov/pubmed/29152091 http://dx.doi.org/10.18632/oncotarget.20558 |
Ejemplares similares
-
Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway
por: Koleini, Navid, et al.
Publicado: (2018) -
Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
por: Koleini, Navid, et al.
Publicado: (2017) -
High Molecular Weight Fibroblast Growth Factor-2 in the Human Heart Is a Potential Target for Prevention of Cardiac Remodeling
por: Santiago, Jon-Jon, et al.
Publicado: (2014) -
A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition
por: Srisakuldee, Wattamon, et al.
Publicado: (2021) -
Together and apart: inhibition of DNA synthesis by connexin-43 and its relationship to transforming growth factor β
por: Jeyaraman, Maya M., et al.
Publicado: (2013)